Home › Funds › Frazier Life Sciences Management, L.P. › PHAT
Frazier Life Sciences Management, L.P. position in PHAT
Phathom Pharmaceuticals, Inc. · Health Care
Frazier Life Sciences Management, L.P. reported holding 12,466,489 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$135.3M, representing 2.95% of its reported portfolio and ranking #9 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s PHAT position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in PHAT in Q3 2023 at 10,109,279 shares (US$104.8M). The position peaked in Q4 2025 at 12,466,489 shares, worth US$206.8M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 12,466,489 shares valued at US$135.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 10.11M | $104.83M | New |
| Q4 2023 | 10.11M | $92.30M | Hold |
| Q1 2024 | 10.11M | $107.36M | Hold |
| Q2 2024 | 10.11M | $104.13M | Hold |
| Q3 2024 | 10.11M | $182.78M | Hold |
| Q4 2024 | 10.11M | $82.09M | Hold |
| Q1 2025 | 10.11M | $63.39M | Hold |
| Q2 2025 | 12.47M | $119.55M | Add |
| Q3 2025 | 12.47M | $146.73M | Hold |
| Q4 2025 | 12.47M | $206.82M | Hold |
| Q1 2026 | 12.47M | $138.50M | Hold |
| Q2 2026 | 12.47M | $135.26M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 30 other funds we track also report a position in PHAT — the largest reported positions include Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.05M sh · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held PHAT?
Frazier Life Sciences Management, L.P. has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in PHAT?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 12.47M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $135.26M, representing 2.95% of its reported portfolio and ranking #9.
Has Frazier Life Sciences Management, L.P. been buying or selling PHAT?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in PHAT. The position peaked in Q4 2025 at 12.47M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., NEA Management Company, LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.